9:41
neuroplast.com
Screenshot of neuroplast.com
neuroplast.com favicon

neuroplast.com

14 technologies
VerifiedGrowingVisit1.2K/mo$2M1014 Tech2 Leads
Deep Dive

Neuroplast: The Autologous Cell Therapy Bet

A Dutch biotech betting on self-healing to tackle neurodegeneration.

While Big Pharma chases generic small molecules, Neuroplast is betting the house on a radical premise: your own cells can rebuild your brain. They aren't just treating symptoms; they are attempting to reverse the irreversible damage caused by trauma and aging.

10
employees
$1.6M
annual revenue
35%
organic search traffic
70M
people affected/year

"The current standard of care for Alzheimer's and Parkinson's is essentially giving up. Neuroplast refuses to accept that."

The Autologous Advantage

Neuroplast isn't developing a one-size-fits-all synthetic drug. Their platform, Neuro-Cells®, utilizes autologous stem cells—meaning the therapy is harvested from and returned to the patient. This eliminates the massive rejection risks and ethical quagmires associated with allogeneic (donor) cells, positioning them as a cleaner, potentially more effective solution for spinal cord and traumatic brain injuries.

The Geleen Edge

Operating out of Geleen, Netherlands, Neuroplast leverages the region's deep biotech infrastructure. Despite having only 10 employees, they are generating $1.6M in revenue—likely from early-stage partnerships or grants. This lean operation suggests a focus on high-value IP generation rather than bloated R&D spend, a model that appeals to disciplined investors.

The market opportunity is staggering. With 70 million people annually suffering from traumatic brain or spinal cord injuries—plus another 70 million fighting Alzheimer's and Parkinson's daily—the total addressable market is in the trillions. Yet, the current global rank of #12.7M indicates they are still in stealth mode, flying under the radar of mainstream biotech investors.

  • First-in-class autologous platform: Avoids immune rejection.
  • Dual-impact focus: Targets both acute trauma (TBI/SCI) and chronic degeneration (Alzheimer's/Parkinson's).
  • Lean execution: $1.6M revenue with a team of 10 suggests high operational efficiency.
Highly dependent on manual cell processing (scalability risk)
Proprietary Neuro-Cells® IP
Low web presence (Global Rank: #12.7M)
Located in the EU biotech hub (Geleen)
No disclosed funding rounds (capital constraints?)
Clear, urgent market need with zero effective competition

The Verdict: A High-Risk, High-Reward Play

Neuroplast is a classic 'deep tech' bet: hard science, small team, massive potential. For investors, the question isn't the market size—it's execution speed.

What tech stack does Neuroplast use?

17 detected
Security1
Error Tracking1
CMS1
Customer Support1
Analytics & Marketing1
Performance1
Web Standards2
Build Tools1
CSS Frameworks1
JavaScript Libraries2
Frontend Frameworks1
Tracking & Analytics3
G
Google Analytics
G
Google Tag Manager
G
Google Analytics

How much traffic does Neuroplast get?

Traffic & Engagement

1.2K
Monthly Visits
1.5
Pages/Visit
0:20
Avg. Duration
39%
Bounce Rate
Monthly Traffic Trend+516%
187
Oct 2025
Oct
618
Nov 2025
Nov
1.2K
Dec 2025
Dec

Traffic Sources

Search
35%
Direct
40%
Social
9%
Referrals
13%
Email
0%
Paid
2%

Where is Neuroplast's audience located?

🌍72.8%
🌍27.2%

What keywords does Neuroplast rank for?

2 keywords
1neuro cells230 vol
2eu neuroplast160 vol

How is Neuroplast's SEO?

Meta Tags

title42 chars

Neuroplast | Stem Cell Technology | Geleen

description105 chars

Global partner in neuro-regenerative medicine. Neuroplast B.V., is a Dutch medical biotechnology company

languageEN

H1 Tags

h1COMBATING NEURODEGENERATION RESULTING FROM TRAUMA, DISEASE AND AGEING WITH AUTOLOGOUS CELL. WORLDWIDE, 70 MILLION PEOPLE PER YEAR SUFFER FROM TRAUMATIC BRAIN INJURY OR SPINAL CORD INJURY. ANOTHER 70 MILLION FIGHT EVERY DAY AGAINST ALZHEIMER’S DISEASE AND/OR PARKINSON’S DISEASE. NO EFFECTIVE TREATMENT EXISTS TODAY. NEUROPLAST AIMS TO RESTORE HOPE FOR MILLIONS OF PEOPLE AFFECTED BY NEURO-DEGENERATIVE IMPAIRMENTS WITH NEURO-CELLS®, A FIRST-IN-KIND AUTOLOGOUS PLATFORM STEM CELL THERAPY.

Schema Types

WebSite

Who works at Neuroplast?

Loading leads...

What do customers think of Neuroplast?

No Trustpilot reviews available for this company.

Frequently Asked Questions about Neuroplast

What is Neuroplast's Revenue?
Neuroplast generates approximately $2M in annual revenue. With 10 employees, that's $155,000 per employee.
What does Neuroplast do?
Global partner in neuro-regenerative medicine. Neuroplast B.V., is a Dutch medical biotechnology company
How fast is Neuroplast growing?
Neuroplast employee count has changed by -64% year over year.
What technologies does Neuroplast use?
Neuroplast uses 14 technologies across their website including Fonts, Security, Error Tracking. Key technologies include Font Awesome, HSTS, Sentry.
Who are Neuroplast's competitors?
Neuroplast's main competitors include Dermavant Sciences, Metrum Research Group, Clovis Oncology, ArcherDX, Inscripta. These companies operate in similar markets and compete for the same customer base.

Export Data

Unlock all exports

Download CSVs, JSONs & full reports

How to contact Neuroplast?

What are Neuroplast's key pages?

Export neuroplast.com Data

Download the complete tech stack, analytics, leads, and company data for neuroplast.com in JSON or CSV format. Use it for your sales pipeline, competitive analysis, or research.

Raw JSON Data

Click "Show" to view the raw API response data

About neuroplast.com

Global partner in neuro-regenerative medicine. Neuroplast B.V., is a Dutch medical biotechnology company

Company Overview

neuroplast.com
Website
#12,754,581
Global Rank
1.2K
Monthly Visitors
14
Technologies
2+
Employees

neuroplast.com Key Pages

Contact neuroplast.com

Technology Stack

neuroplast.com uses 14 technologies across their website including Font Awesome, HSTS, Sentry, and more.

Fonts

Font Awesome

Security

HSTS

Error Tracking

Sentry

CMS

Wix

Customer Support

Zendesk

Analytics & Marketing

Google Analytics

Traffic & Audience

1.2K
Monthly Visits
39%
Bounce Rate
1.5
Pages/Visit
0:20
Avg. Duration

neuroplast.com receives approximately 1.2K monthly visitors and ranks #12,754,581 globally. The website has a bounce rate of 39% with visitors viewing an average of 1.5 pages per visit. Users spend an average of 0:20 on the site.

The majority of neuroplast.com's traffic comes from undefined, .

Frequently Asked Questions

What is neuroplast.com?
Global partner in neuro-regenerative medicine. Neuroplast B.V., is a Dutch medical biotechnology company
What technologies does neuroplast.com use?
neuroplast.com uses 14 technologies including Font Awesome, HSTS, and 8 more. View the full tech stack analysis above.
How do I contact neuroplast.com?
You can contact neuroplast.com via email at [email protected] or through their contact page.
Is neuroplast.com hiring?
Check neuroplast.com's careers page for current job openings and opportunities. The company has 2+ known employees.
How popular is neuroplast.com?
neuroplast.com receives approximately 1.2K monthly visitors and ranks #12,754,581 globally. Traffic is growing by 86.4% month-over-month.

Related Searches

neuroplast.com pricingneuroplast.com reviewsneuroplast.com alternativesneuroplast.com loginneuroplast.com careerswhat is neuroplast.comneuroplast.com tech stackneuroplast.com contactneuroplast.com vs competitorsneuroplast.com featureshow to use neuroplast.comneuroplast.com integrations

This page provides publicly available information about neuroplast.com. Data is collected from various public sources and may not always be up to date. For the most accurate information, please visit neuroplast.com directly at https://neuroplast.com.